Is NCT02474160 recruiting in Fort Smith, AR?

Yes, NCT02474160 is currently recruiting participants at its Fort Smith, AR location. This hematopoietic and lymphatic system neoplasm clinical trial is actively enrolling qualified participants.

Is participation in this Fort Smith clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Hematopoietic and Lymphatic System Neoplasm Clinical Trial in Fort Smith, AR

Q: How do I join the hematopoietic and lymphatic system neoplasm clinical trial in Fort Smith?

To join this clinical trial in Fort Smith, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Hematopoietic and Lymphatic System Neoplasm Study in Fort Smith

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.

Sponsor: National Cancer Institute LAO

Who Can Participate

Inclusion Criteria

Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites

Patients with a histologically or cytologically confirmed diagnosis of cancer

Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator

Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:

Radiographic imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], etc.)

Elevated tumor markers

Clinical symptoms

Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome

Complete blood count (CBC) w/differential indicative of a probable hematologic malignancy

If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred

Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final histology must be confirmed to the coordinating site detailing the cancer diagnosis for patients enrolled based on the above criteria

Patients with a newly diagnosed primary and/or metastatic solid tumor or hematologic malignancy for which they have not yet received treatment

Patients with a solid tumor or hematologic malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:

Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR

Documentation by the treating physician of clinical disease progression, OR

CBC w/differential and/or flow cytometry for hematologic malignancies

Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)

Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)

Specimens should not be collected from patients between doses within a single treatment cycle

Confirmation of viable residual malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report

Patients with ongoing partial response (PR) or stable disease (SD) are eligible

Confirmation of viable malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report

Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol

For pediatric patients, ability and willingness to assent to participation, using an explanation that is understandable/age appropriate, as well as receiving parental permission. Signature requirements for pediatric patients can be adjusted based on local guidelines

Exclusion Criteria

Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)

Patients with invasive fungal infections

Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection

Actively febrile patients with uncertain etiology of febrile episode

All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection

Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded

No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics

Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible

Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible

Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus \[HBV\]-deoxyribonucleic acid \[DNA\] and/or positive hepatitis B surface antigen \[HbsAg\], quantifiable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated

Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity

Patients that are anti-HAV IgG reactive only are eligible

Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Smith?

Yes, this clinical trial (NCT02474160) has an active research site in Fort Smith, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematopoietic and Lymphatic System Neoplasm Treatment Options in Fort Smith, AR

If you're searching for hematopoietic and lymphatic system neoplasm treatment options in Fort Smith, AR, this clinical trial (NCT02474160) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Smith research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematopoietic and lymphatic system neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematopoietic and lymphatic system neoplasm clinical trials near you to find additional studies recruiting in your area.

Hematopoietic and Lymphatic System Neoplasm Clinical Trial in Fort Smith, AR

Expert Care in Fort Smith

IRB Approved

No-Cost Care

Apply for This Fort Smith Location

Why Participate?

Simple Process